Acta neurochirurgica · 2011
Rosiglitazone ameliorates the histological parameters of the dorsal root ganglion and functional assessment after sciatic nerve injury in the rat.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Noorafshan Ali, Shariat Khatoon, Karbalay-Doust Saied, Omidi Amene
Аннотация
BACKGROUND: This study investigates the effects of rosiglitazone (a peroxisome proliferator-activated receptor-gamma) on the histological parameters of the dorsal root ganglion (DRG) and the recovery potential of the injured sciatic nerve in rats using stereological methods.
METHODS: The rats were divided into four groups including control, sham-operated, sciatic nerve crush (SNC), and SNC + rosiglitazone treatment (5 mg/kg body weight/day). The sciatic functional index (SFI) was used to evaluate functional recovery. The main DRG neurons were defined as either A cells (the larger cell with a central nucleolus in the nucleus and granulated cytoplasm) or B cells (the smaller cell with multiple peripherally located nucleoli and homogenous cytoplasm). Satellite cells (supporting) surround the neuron cell body.
RESULTS: The volume and surface of A and B cells decreased in the SNC group compared to the sham-operated group. In the SNC + rosiglitazone group, the volume of A and B cells decreased to a lesser extent, and was 30% and 48% higher in comparison with the SCN group. In the SNC + rosiglitazone rats the surface of the A and B cells decreased to a minor extent, and was 45% and 21% higher in comparison with the SNC animals. In rosiglitazone-treated rats the number of the A, B, and satellite cells decreased less, and was 38%, 34%, and 29% higher than in the SNC rats. The SFI score improved in SNC + rosiglitazone rats in comparison with non-treated animals.
CONCLUSION: Rosiglitazone has an ameliorative effect on the DRG and enhances the functional recovery after SNC in rats.
METHODS: The rats were divided into four groups including control, sham-operated, sciatic nerve crush (SNC), and SNC + rosiglitazone treatment (5 mg/kg body weight/day). The sciatic functional index (SFI) was used to evaluate functional recovery. The main DRG neurons were defined as either A cells (the larger cell with a central nucleolus in the nucleus and granulated cytoplasm) or B cells (the smaller cell with multiple peripherally located nucleoli and homogenous cytoplasm). Satellite cells (supporting) surround the neuron cell body.
RESULTS: The volume and surface of A and B cells decreased in the SNC group compared to the sham-operated group. In the SNC + rosiglitazone group, the volume of A and B cells decreased to a lesser extent, and was 30% and 48% higher in comparison with the SCN group. In the SNC + rosiglitazone rats the surface of the A and B cells decreased to a minor extent, and was 45% and 21% higher in comparison with the SNC animals. In rosiglitazone-treated rats the number of the A, B, and satellite cells decreased less, and was 38%, 34%, and 29% higher than in the SNC rats. The SFI score improved in SNC + rosiglitazone rats in comparison with non-treated animals.
CONCLUSION: Rosiglitazone has an ameliorative effect on the DRG and enhances the functional recovery after SNC in rats.